No Data
No Data
Today's flows: 02/26 Fujikura saw an inflow of JPY¥ 3.68 billion, Tokyo Electron saw an outflow of JPY¥ 17.25 billion
On February 26th, the TSE Main Market saw an inflow of JPY¥ 751.19 billion and an outflow of JPY¥ 826.7 billion.$Fujikura(5803.JP)$, $Sony Group(6758.JP)$ and $IHI(7013.JP)$ were net buyers of JPY¥ 3.
Petroleum resources, light industry, etc. (additional) Rating
Upgraded - Bullish Code Stock Name Brokerage Firm Previous Changed After-------------------------------------------------------------<268A> Rigaku Nomura "Hold" "Buy" <3626> TIS GS "Hold" "Buy" <4528> Ono Pharmaceutical City "3" "2" <6752> Panasonic HD Morgan Stanley "Equal Weight" "Over Weight" <7735> Screen Morgan Stanley "Equal Weight" "Over Weight"
Rating information (Target Price change - Part 1) = Nisshin Oil, Oji Holdings, ETC.
◎ Nomura Securities (three-stage: Buy > Neutral > Reduce) Nichiyo <4403.T> -- "Buy" → "Buy", 2,880 yen → 2,960 yen M&A Cap <6080.T> -- "Buy" → "Buy", 4,400 yen → 4,500 yen SMC <6273.T> -- "Buy" → "Buy", 95,000 yen → 80,000 yen CKD <6407.T> -- "Buy" → "Buy", 4,000 yen → 3,400 yen Yokogawa Electric <6841.T> -- "Buy" → "Buy",
Rating Information (Investment Decision Change - Part 2) = Chugai Pharmaceutical, SUBARU, ETC.
◎ SBI Securities (three levels: Buy > Hold > Sell) Chugai Pharmaceutical <4519.T> -- New "Buy", 9,000 yen Ion <8267.T> -- New "Hold", 4,000 yen Fast Retailing <9983.T> -- New "Hold", 50,000 yen ◎ JP Morgan Securities (three levels: Overweight > neutral > Underweight SUBARU <7270.T> -- "Neutral" → "Underweight", 2,700 yen → 2,500 yen ◎ Goldman Sachs Group Inc (three
AI needs to be cautious and is wary of the tightening of semiconductor regulations against China.
The Nikkei average fell sharply. It ended trading at 38,237.79 yen, down 539.15 yen (estimated Volume of 1.9 billion 60 million shares). Selling started early due to the decline in US tech stocks, and the index dropped to 38,131.79 yen just after the trading began. Subsequently, targeting a self-rebound and with buying in trading company stocks, it recovered to 38,485.95 yen toward the end of the morning session. However, aggressive rebound movements were limited, continuing to consolidate around 38,300 yen. The Tokyo Stock Exchange Main Board's
Celltrion Receives EC Approval for Avtozma (CT-P47), a Biosimilar to RoActemra (Tocilizumab)